Emily Chan

TL;DR: It is found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands, and the observation that hepatocyte growth factor confers resistance to the BRAF inhibitor PLX4032 in BRAF-mutant melanoma cells is among the findings with clinical implications.

TL;DR: It is found that the ERBB3 mutants transformed colonic and breast epithelial cells in a ligand-independent manner, however, the mutant ER BB3 oncogenic activity was dependent on kinase-active ERBB2.

TL;DR: A potent and specific small-molecule tankyrase inhibitors are developed that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β- catenin destabilization and establishing proof-of-concept antitumor efficacy for tankyrases in APC-mutant CRC models.

TL;DR: A chemical genetics approach is used to acutely block the function of the cAMP response element binding protein (CREB) binding protein (CBP)/P300 bromodomain in models of hematological malignancies and describes a consequent loss of H3K27Ac specifically from enhancers, despite the continued presence of CBP/P300 at chromatin.

TL;DR: These findings offer a preclinical proof of concept for small-molecule therapies to target the CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer.